A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE
NCT00063791 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2007-02-14
Summary
The purpose of this study is to give patients who have had 4 or more prior lines of therapy for multiple myeloma access to VELCADE. The study is for patients who are not eligible for other clinical trials with VELCADE and for who VELCADE would otherwise not be available.
Conditions
Interventions
- DRUG
Sponsors & Collaborators
-
Millennium Pharmaceuticals, Inc.
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma
NCT00560352 ·Status: TERMINATED ·Phase: PHASE1
-
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
NCT00507416 ·Status: COMPLETED ·Phase: PHASE3
-
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106 ·Status: TERMINATED ·Phase: PHASE2
-
Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse
NCT00335348 ·Status: COMPLETED ·Phase: PHASE2
-
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT03701321 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
NCT00507442 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00048230 ·Status: COMPLETED ·Phase: PHASE3
-
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT03110562 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
NCT00135187 ·Status: COMPLETED ·Phase: NA
-
Microdose Study of Melphalan, Bortezomib and Dexamethasone
NCT02109861 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
NCT00389701 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
NCT01084837 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone
NCT00522392 ·Status: TERMINATED ·Phase: PHASE3
-
Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma
NCT00378209 ·Status: COMPLETED ·Phase: PHASE2
-
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
NCT00116961 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT00438841 ·Status: UNKNOWN ·Phase: PHASE2
-
Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)
NCT00910897 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib
NCT01910987 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT02755597 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
NCT01568866 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma
NCT00718601 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00257114 ·Status: COMPLETED ·Phase: PHASE4
-
Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
NCT00483262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
NCT02195479 ·Status: COMPLETED ·Phase: PHASE3